10x Genomics (TXG) Short-term Investments (2020 - 2026)

10x Genomics has disclosed Short-term Investments across 7 years of filings, most recently posting $49.6 million for Q1 2026.

• Short-term Investments for Q1 2026 came in at $49.6 million, down 0.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.6 million (down 0.56% YoY), and the FY2025 annual result was $49.4 million, changed 0.22% from the prior year.
• Short-term Investments came in at $49.6 million for Q1 2026 at 10x Genomics, roughly flat from $49.4 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $226.8 million in Q1 2022 to a low of $269000.0 in Q2 2024.
• The 5-year median for Short-term Investments is $47.5 million (2023), against an average of $42.9 million.
• Across the five-year window, Short-term Investments tumbled 99.59% in 2024 and surged 18319.7% in 2025, its largest moves.
• 10x Genomics' Short-term Investments stood at $2.6 million in 2022, then surged by 1017.01% to $29.4 million in 2023, then soared by 67.74% to $49.3 million in 2024, then gained by 0.22% to $49.4 million in 2025, then advanced by 0.24% to $49.6 million in 2026.
• The last three Short-term Investments figures came in at $49.6 million (Q1 2026), $49.4 million (Q4 2025), and $49.6 million (Q3 2025), per Business Quant data.